New Delhi: Drug Controller General of India (DCGI) on Friday approved restricted emergency use of Zydus Cadila’s ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infections in adults.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup,” the company said in a filing.
New Delhi: The Bombay High Court on Wednesday granted bail to gangster Chhota Rajan, suspending…
Bhubaneswar: Odisha Vigilance sleuths on Wednesday apprehended in-charge RI of Sindurpur Revenue Circle under Binka…
Bhubaneswar: With severe cyclonic storm ‘Dana’ set to hit the Odisha coast by October 25.,…
New Delhi: A breast cancer awareness campaign by cricketer Yuvraj Singh's non-profit 'YouWeCan' is being…
Bhubaneswar/Cuttack: The Odisha government on Wednesday signed a memorandum of understanding (MoU) with Chennai-based MGM…
Bhubaneswar: The Odisha Civil Services (OCS) Preliminary Examination-2023 scheduled to be held on October 27…
New Delhi: A Hyderabad cab driver’s warning note to passengers, particularly couples, has captured the…
Bhubaneswar: The Mohan Majhi government is preparing to tackle Cyclone 'Dana, which is likely to…